REFERENCES
1. Chung KF, Adcock IM. Precision medicine for the discovery of treatable mechanisms in severe asthma. Allergy.2019;74(9):1649-1659.
2. Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. J Clin Invest. 2019;129(4):1493-1503.
3. Olafsdottir TA, Theodors F, Bjarnadottir K, et al. Eighty-eight variants highlight the role of T cell regulation and airway remodeling in asthma pathogenesis. Nat Commun. 2020;11(1):393.
4. Guo Y, Moon JY, Laurie CC, et al. Genetic predisposition to obesity is associated with asthma in US Hispanics/Latinos: Results from the Hispanic Community Health Study/Study of Latinos. Allergy.2018;73(7):1547-1550.
5. D’Amato G, Annesi-Maesano I, Cecchi L, D’Amato M. Latest news on relationship between thunderstorms and respiratory allergy, severe asthma, and deaths for asthma. Allergy. 2019;74(1):9-11.
6. Kim J, Kim YC, Ham J, et al. The effect of air pollutants on airway innate immune cells in patients with asthma. Allergy. 2020.
7. Celebi Sözener Z, Cevhertas L, Nadeau K, Akdis M, Akdis CA. Environmental factors in epithelial barrier dysfunction. J Allergy Clin Immunol. 2020;145(6):1517-1528.
8. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet.2018;391(10122):783-800.
9. Borna E, Nwaru BI, Bjerg A, et al. Changes in the prevalence of asthma and respiratory symptoms in western Sweden between 2008 and 2016.Allergy. 2019;74(9):1703-1715.
10. Branco PTBS, Alvim-Ferraz MCM, Martins FG, Ferraz C, Vaz LG, Sousa SIV. Asthma in urban and rural pre- and primary schoolchildren according to the latest GINA definition. Allergy. 2020;75(7):1771-1776.
11. Liu X, Andersen SL, Olsen J, et al. Maternal hypothyroidism in the perinatal period and childhood asthma in the offspring. Allergy.2018;73(4):932-939.
12. Odling M, Andersson N, Ekstrom S, Melen E, Bergstrom A, Kull I. Characterization of asthma in the adolescent population. Allergy.2018;73(8):1744-1746.
13. Keller T, Hohmann C, Standl M, et al. The sex-shift in single disease and multimorbid asthma and rhinitis during puberty - a study by MeDALL. Allergy. 2018;73(3):602-614.
14. Farzan N, Vijverberg SJ, Hernandez-Pacheco N, et al. 17q21 variant increases the risk of exacerbations in asthmatic children despite inhaled corticosteroids use. Allergy. 2018;73(10):2083-2088.
15. Gorlanova O, Illi S, Toncheva AA, et al. Protective effects of breastfeeding on respiratory symptoms in infants with 17q21 asthma risk variants. Allergy. 2018;73(12):2388-2392.
16. Hur GY, Pham A, Miller M, et al. ORMDL3 but not neighboring 17q21 gene LRRC3C is expressed in human lungs and lung cells of asthmatics.Allergy. 2020.
17. Agusti A, Faner R. Lung function trajectories in health and disease.Lancet Respir Med. 2019;7(4):358-364.
18. Krautenbacher N, Flach N, Bock A, et al. A strategy for high-dimensional multivariable analysis classifies childhood asthma phenotypes from genetic, immunological, and environmental factors.Allergy. 2019;74(7):1364-1373.
19. Dijk FN, Vijverberg SJ, Hernandez-Pacheco N, et al. IL1RL1 gene variations are associated with asthma exacerbations in children and adolescents using inhaled corticosteroids. Allergy.2020;75(4):984-989.
20. Agache I, Miller R, Gern JE, et al. Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma: a Practall document. Allergy. 2019;74(3):449-463.
21. Yang SI, Lee SY, Kim HB, et al. Prenatal particulate matter affects new asthma via airway hyperresponsiveness in schoolchildren.Allergy. 2019;74(4):675-684.
22. Paciencia I, Cavaleiro Rufo J, Silva D, et al. Exposure to indoor endocrine-disrupting chemicals and childhood asthma and obesity.Allergy. 2019;74(7):1277-1291.
23. Brandt EB, Bolcas PE, Ruff BP, Khurana Hershey GK. IL33 contributes to diesel pollution-mediated increase in experimental asthma severity.Allergy. 2020.
24. Agache I, Annesi-Maesano I, Bonertz A, et al. Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases. Allergy. 2019;74(11):2064-2076.
25. Weng CM, Wang CH, Lee MJ, et al. Aryl hydrocarbon receptor activation by diesel exhaust particles mediates epithelium-derived cytokines expression in severe allergic asthma. Allergy.2018;73(11):2192-2204.
26. Wang E, Liu X, Tu W, et al. Benzo(a)pyrene facilitates dermatophagoides group 1 (Der f 1)-induced epithelial cytokine release through aryl hydrocarbon receptor in asthma. Allergy.2019;74(9):1675-1690.
27. Gao Z, Fu WY, Sun Y, et al. Artemisia pollen allergy in China: Component-resolved diagnosis reveals allergic asthma patients have significant multiple allergen sensitization. Allergy.2019;74(2):284-293.
28. Hernández-Ramírez G, Pazos-Castro D, Gómez Torrijos E, et al. Group 1 allergens, transported by mold spores, induce asthma exacerbation in a mouse model. Allergy. 2020.
29. Watai K, Fukutomi Y, Hayashi H, et al. De novo sensitization to Aspergillus fumigatus in adult asthma over a 10-year observation period.Allergy. 2018;73(12):2385-2388.
30. Sullivan A, Hunt EB, Ward C, et al. The presence of Aspergillus fumigatus in asthmatic airways is not clearly related to clinical disease severity. Allergy. 2020;75(5):1146-1154.
31. Hew M, Lee J, Susanto NH, et al. The 2016 Melbourne thunderstorm asthma epidemic: Risk factors for severe attacks requiring hospital admission. Allergy. 2019;74(1):122-130.
32. Hew M, Lee J, Varese N, et al. Epidemic thunderstorm asthma susceptibility from sensitization to ryegrass (Lolium perenne) pollen and major allergen Lol p 5. Allergy. 2020.
33. Erbas B, Jazayeri M, Lambert KA, et al. Outdoor pollen is a trigger of child and adolescent asthma emergency department presentations: A systematic review and meta-analysis. Allergy.2018;73(8):1632-1641.
34. Kim SY, Sim S, Choi HG. Active and passive smoking impacts on asthma with quantitative and temporal relations: A Korean Community Health Survey. Sci Rep. 2018;8(1):8614.
35. McAlinden KD, Naidu V, Sohal SS, Sharma P. In utero Exposure to Nicotine Containing Electronic Cigarettes Increases the Risk of Allergic Asthma in Female Offspring. Am J Physiol Lung Cell Mol Physiol.2020.
36. Eddy RL, Serajeddini H, Knipping D, et al. Pulmonary Functional MRI and CT in a Survivor of Bronchiolitis and Respiratory Failure Caused by e-Cigarette Use. Chest. 2020.
37. Adkins SH, Anderson KN, Goodman AB, et al. Demographics, Substance Use Behaviors, and Clinical Characteristics of Adolescents With e-Cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) in the United States in 2019. JAMA Pediatr. 2020:e200756.
38. Werner AK, Koumans EH, Chatham-Stephens K, et al. Hospitalizations and Deaths Associated with EVALI. N Engl J Med.2020;382(17):1589-1598.
39. Chung SJ, Kim BK, Oh JH, et al. Novel tobacco products including electronic cigarette and heated tobacco products increase risk of allergic rhinitis and asthma in adolescents: Analysis of Korean youth survey. Allergy. 2020;75(7):1640-1648.
40. Venter C, Meyer RW, Nwaru BI, et al. EAACI position paper: Influence of dietary fatty acids on asthma, food allergy, and atopic dermatitis.Allergy. 2019;74(8):1429-1444.
41. Venter C, Greenhawt M, Meyer RW, et al. EAACI position paper on diet diversity in pregnancy, infancy and childhood: Novel concepts and implications for studies in allergy and asthma. Allergy.2020;75(3):497-523.
42. Kang SY, Song WJ, Kim MH, et al. Dietary assessment and the development of asthma in Korean adolescents and adults. Allergy.2018;73(11):2254-2256.
43. Comberiati P, Peroni DG. Vitamin D supplementation in pregnancy does not prevent school-age asthma. Allergy. 2020.
44. Litonjua AA, Carey VJ, Laranjo N, et al. Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction. N Engl J Med.2020;382(6):525-533.
45. Hennessy A, Hourihane JO, Malvisi L, et al. Antenatal vitamin D exposure and childhood eczema, food allergy, asthma and allergic rhinitis at 2 and 5 years of age in the atopic disease-specific Cork BASELINE Birth Cohort Study. Allergy. 2018;73(11):2182-2191.
46. Tomita Y, Fukutomi Y, Irie M, et al. Acid-suppressive medication as a possible risk factor for late-onset asthma. Allergy.2020;75(5):1247-1250.
47. Barcik W, Boutin RCT, Sokolowska M, Finlay BB. The Role of Lung and Gut Microbiota in the Pathology of Asthma. Immunity.2020;52(2):241-255.
48. Sbihi H, Boutin RC, Cutler C, Suen M, Finlay BB, Turvey SE. Thinking bigger: How early-life environmental exposures shape the gut microbiome and influence the development of asthma and allergic disease.Allergy. 2019;74(11):2103-2115.
49. Walter J, O’Mahony L. The importance of social networks-An ecological and evolutionary framework to explain the role of microbes in the aetiology of allergy and asthma. Allergy.2019;74(11):2248-2251.
50. Stokholm J, Blaser MJ, Thorsen J, et al. Maturation of the gut microbiome and risk of asthma in childhood. Nat Commun.2018;9(1):141.
51. Bannier MAGE, van Best N, Bervoets L, et al. Gut microbiota in wheezing preschool children and the association with childhood asthma.Allergy. 2020;75(6):1473-1476.
52. Lee JJ, Kim SH, Lee MJ, et al. Different upper airway microbiome and their functional genes associated with asthma in young adults and elderly individuals. Allergy. 2019;74(4):709-719.
53. Kim BS, Lee E, Lee MJ, et al. Different functional genes of upper airway microbiome associated with natural course of childhood asthma.Allergy. 2018;73(3):644-652.
54. Spacova I, Petrova MI, Fremau A, et al. Intranasal administration of probiotic Lactobacillus rhamnosus GG prevents birch pollen-induced allergic asthma in a murine model. Allergy. 2019;74(1):100-110.
55. Roßberg S, Keller T, Icke K, et al. Orally applied bacterial lysate in infants at risk for atopy does not prevent atopic dermatitis, allergic rhinitis, asthma or allergic sensitization at school age: Follow-up of a randomized trial. Allergy. 2020.
56. Alhasan MM, Cait AM, Heimesaat MM, et al. Antibiotic use during pregnancy increases offspring asthma severity in a dose-dependent manner. Allergy. 2020.
57. Eguiluz-Gracia I, Mathioudakis AG, Bartel S, et al. The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma. Allergy. 2020.
58. Rahimi RA, Nepal K, Cetinbas M, Sadreyev RI, Luster AD. Distinct functions of tissue-resident and circulating memory Th2 cells in allergic airway disease. J Exp Med. 2020;217(9).
59. Vieira Braga FA, Kar G, Berg M, et al. A cellular census of human lungs identifies novel cell states in health and in asthma. Nat Med. 2019;25(7):1153-1163.
60. Asayama K, Kobayashi T, D’Alessandro-Gabazza CN, et al. Protein S protects against allergic bronchial asthma by modulating Th1/Th2 balance. Allergy. 2020.
61. Bolcas PE, Brandt EB, Ruff BP, Kalra M, Khurana Hershey GK. Cysteamine prevents asthma development and reduces airway hyperresponsiveness in experimental asthma. Allergy. 2020.
62. Lu Y, Kared H, Tan SW, et al. Dynamics of helper CD4 T cells during acute and stable allergic asthma. Mucosal Immunol.2018;11(6):1640-1652.
63. Khumalo J, Kirstein F, Scibiorek M, Hadebe S, Brombacher F. Therapeutic and prophylactic deletion of IL-4Ra-signaling ameliorates established ovalbumin induced allergic asthma. Allergy.2020;75(6):1347-1360.
64. Ro M, Lee AJ, Kim JH. 5-/12-Lipoxygenase-linked cascade contributes to the IL-33-induced synthesis of IL-13 in mast cells, thus promoting asthma development. Allergy. 2018;73(2):350-360.
65. Lv J, Xiong Y, Li W, et al. IL-37 inhibits IL-4/IL-13-induced CCL11 production and lung eosinophilia in murine allergic asthma.Allergy. 2018;73(8):1642-1652.
66. Russkamp D, Aguilar-Pimentel A, Alessandrini F, et al. IL-4 receptor α blockade prevents sensitization and alters acute and long-lasting effects of allergen-specific immunotherapy of murine allergic asthma.Allergy. 2019;74(8):1549-1560.
67. Hong JY, Kim M, Sol IS, et al. Chitotriosidase inhibits allergic asthmatic airways via regulation of TGF-β expression and Foxp3.Allergy. 2018;73(8):1686-1699.
68. Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020;75(2):311-325.
69. Worth L, Michel S, Gaertner VD, Kabesch M, Schieck M. Asthma- and IgE-associated polymorphisms affect expression of TH 17 genes.Allergy. 2018;73(6):1342-1347.
70. Ro M, Kwon SY, Kim JH. Leukotriene B4 receptors mediate the production of IL-17, thus contributing to neutrophil-dominant asthmatic airway inflammation. Allergy. 2019;74(9):1797-1799.
71. Ekstedt S, Stenberg H, Tufvesson E, et al. The potential role of CD16(high) CD62L(dim) neutrophils in the allergic asthma.Allergy. 2019;74(11):2265-2268.
72. Brown GC, Vilalta A, Fricker M. Phagoptosis - Cell Death By Phagocytosis - Plays Central Roles in Physiology, Host Defense and Pathology. Current molecular medicine. 2015;15(9):842–851.
73. Ekstedt S, Tufvesson E, Bjermer L, Kumlien Georén S, Cardell LO. A new role for ”eat me” and ”don’t eat me” markers on neutrophils in asthmatic airway inflammation. Allergy. 2020;75(6):1510–1512.
74. Guan Q, Yang B, Warrington RJ, et al. Myeloid-derived suppressor cells: Roles and relations with Th2, Th17, and Treg cells in asthma.Allergy. 2019;74(11):2233-2237.
75. Wirz OF, Globinska A, Ochsner U, et al. Comparison of regulatory B cells in asthma and allergic rhinitis. Allergy.2019;74(4):815-818.
76. Brightling CE, Brusselle G, Altman P. The impact of the prostaglandin D2 receptor 2 and its downstream effects on the pathophysiology of asthma. Allergy. 2020;75(4):761-768.
77. Moon HG, Kim SJ, Lee MK, et al. Colony-stimulating factor 1 and its receptor are new potential therapeutic targets for allergic asthma.Allergy. 2020;75(2):357-369.
78. Kim S-H, Jung H-W, Kim M, et al. Ceramide/sphingosine-1-phosphate imbalance is associated with distinct inflammatory phenotypes of uncontrolled asthma. Allergy. 2020.
79. Choi Y, Kim M, Kim SJ, Yoo H-J, Kim S-H, Park H-S. Metabolic shift favoring C18:0 ceramide accumulation in obese asthma. Allergy.2020.
80. Felix MMR, Kuschnir FC. Arginase inhibitors: An alternative in treatment of obese asthma? Allergy. 2020;75(6):1525–1526.
81. Meurs H, Zaagsma J, Maarsingh H, van Duin M. Recent Patents in Allergy/Immunology: Use of arginase inhibitors in the treatment of asthma and allergic rhinitis. Allergy. 2019;74(6):1206–1208.
82. Meurs H, Zaagsma J, Maarsingh H, van Duin M. Reply to: ”Arginase inhibitors: An alternative in treatment of obese asthma?”.Allergy. 2020;75(6):1527–1528.
83. Ferreira DS, Carvalho-Pinto RM, Gregorio MG, et al. Airway pathology in severe asthma is related to airflow obstruction but not symptom control. Allergy. 2018;73(3):635-643.
84. Asaduzzaman M, Davidson C, Nahirney D, Fiteih Y, Puttagunta L, Vliagoftis H. Proteinase-activated receptor-2 blockade inhibits changes seen in a chronic murine asthma model. Allergy.2018;73(2):416-420.
85. Altman MC, Gill MA, Whalen E, et al. Transcriptome networks identify mechanisms of viral and nonviral asthma exacerbations in children.Nat Immunol. 2019;20(5):637-651.
86. Hasegawa K, Hoptay CE, Harmon B, et al. Association of type 2 cytokines in severe rhinovirus bronchiolitis during infancy with risk of developing asthma: A multicenter prospective study. Allergy.2019;74(7):1374-1377.
87. Lund RJ, Osmala M, Malonzo M, et al. Atopic asthma after rhinovirus-induced wheezing is associated with DNA methylation change in the SMAD3 gene promoter. Allergy. 2018;73(8):1735-1740.
88. Schuler CF, Malinczak C-A, Best SKK, et al. Inhibition of uric acid or IL-1β ameliorates respiratory syncytial virus immunopathology and development of asthma. Allergy. 2020.
89. Törmänen S, Lauhkonen E, Riikonen R, et al. Risk factors for asthma after infant bronchiolitis. Allergy. 2018;73(4):916-922.
90. Schwarze J, Openshaw P, Jha A, et al. Influenza burden, prevention, and treatment in asthma-A scoping review by the EAACI Influenza in asthma task force. Allergy. 2018;73(6):1151-1181.
91. Yu QN, Guo YB, Li X, et al. ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma. Allergy. 2018;73(9):1860-1870.
92. Milara J, Morell A, de Diego A, Artigues E, Morcillo E, Cortijo J. Mucin 1 deficiency mediates corticosteroid insensitivity in asthma.Allergy. 2019;74(1):111-121.
93. Bartel S, La Grutta S, Cilluffo G, et al. Human airway epithelial extracellular vesicle miRNA signature is altered upon asthma development. Allergy. 2020;75(2):346-356.
94. Suojalehto H, Lindstrom I, Wolff H, Puustinen A. Nasal protein profiles in work-related asthma caused by different exposures.Allergy. 2018;73(3):653-663.
95. Uwadiae FI, Pyle CJ, Walker SA, Lloyd CM, Harker JA. Targeting the ICOS/ICOS-L pathway in a mouse model of established allergic asthma disrupts T follicular helper cell responses and ameliorates disease.Allergy. 2019;74(4):650-662.
96. Bateman ED, Reddel HK, van Zyl-Smit RN, Agusti A. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med. 2015;3(9):719-728.
97. Wang YC, Jaakkola MS, Lajunen TK, Lai CH, Jaakkola JJK. Asthma-COPD Overlap Syndrome among subjects with newly diagnosed adult-onset asthma.Allergy. 2018;73(7):1554-1557.
98. Campo P, Eguiluz-Gracia I, Plaza-Seron MC, et al. Bronchial asthma triggered by house dust mites in patients with local allergic rhinitis.Allergy. 2019;74(8):1502-1510.
99. Toppila-Salmi S, Chanoine S, Karjalainen J, Pekkanen J, Bousquet J, Siroux V. Risk of adult-onset asthma increases with the number of allergic multimorbidities and decreases with age. Allergy.2019;74(12):2406-2416.
100. Samitas K, Carter A, Kariyawasam HH, Xanthou G. Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: The one airway concept revisited. Allergy.2018;73(5):993-1002.
101. Sharma N, Akkoyunlu M, Rabin RL. Macrophages-common culprit in obesity and asthma. Allergy. 2018;73(6):1196-1205.
102. Chen YC, Fan HY, Yang C, Lee YL. Early pubertal maturation and risk of childhood asthma: A Mendelian randomization and longitudinal study.Allergy. 2020;75(4):892-900.
103. Skaaby T, Taylor AE, Thuesen BH, et al. Estimating the causal effect of body mass index on hay fever, asthma and lung function using Mendelian randomization. Allergy. 2018;73(1):153-164.
104. Tay TR, Hew M. Comorbid ”treatable traits” in difficult asthma: Current evidence and clinical evaluation. Allergy.2018;73(7):1369-1382.
105. Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy.2019;74(12):2312-2319.
106. Li Y, Jiang Q, Ji Y, Cao C. Anxiety and depression may associate with poorer control and quality of life in adults with asthma.Allergy. 2020;75(7):1759-1762.
107. Lemonnier N, Melén E, Jiang Y, et al. A novel whole blood gene expression signature for asthma, dermatitis, and rhinitis multimorbidity in children and adolescents. Allergy. 2020.
108. Siroux V, Ballardini N, Soler M, et al. The asthma-rhinitis multimorbidity is associated with IgE polysensitization in adolescents and adults. Allergy. 2018;73(7):1447-1458.
109. Lemmetyinen RE, Karjalainen JV, But A, et al. Higher mortality of adults with asthma: A 15-year follow-up of a population-based cohort.Allergy. 2018;73(7):1479-1488.
110. Postma DS, Brightling C, Baldi S, et al. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respir Med.2019;7(5):402-416.
111. Shirai T, Akamatsu T, Hirai K, et al. Oscillometry improves earlier than spirometry after benralizumab initiation in severe asthma.Allergy. 2020.
112. Dunn RM, Busse PJ, Wechsler ME. Asthma in the elderly and late-onset adult asthma. Allergy. 2018;73(2):284-294.
113. Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper.Allergy. 2019;74(1):28-39.
114. Diamant Z, Vijverberg S, Alving K, et al. Toward clinically applicable biomarkers for asthma: An EAACI position paper.Allergy. 2019;74(10):1835-1851.
115. Celejewska-Wójcik N, Wójcik K, Ignacak-Popiel M, et al. Subphenotypes of nonsteroidal antiinflammatory disease-exacerbated respiratory disease identified by latent class analysis. Allergy.2020;75(4):831-840.
116. Mastalerz L, Tyrak KE, Ignacak M, et al. Prostaglandin E2 decrease in induced sputum of hypersensitive asthmatics during oral challenge with aspirin. Allergy. 2019;74(5):922-932.
117. Chen LC, Tseng HM, Kuo ML, et al. A composite of exhaled LTB4 , LXA4 , FeNO, and FEV1 as an ”asthma classification ratio” characterizes childhood asthma. Allergy. 2018;73(3):627-634.
118. Tanaka H, Nakatani E, Fukutomi Y, et al. Identification of patterns of factors preceding severe or life-threatening asthma exacerbations in a nationwide study. Allergy. 2018;73(5):1110-1118.
119. Jutel M, Brüggenjürgen B, Richter H, Vogelberg C. Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma. Allergy. 2020.
120. Suarthana E, Taghiakbari M, Saha-Chaudhuri P, et al. The validity of the Canadian clinical scores for occupational asthma in European populations. Allergy. 2020.
121. Vandenplas O, Godet J, Hurdubaea L, et al. Are high- and low-molecular-weight sensitizing agents associated with different clinical phenotypes of occupational asthma? Allergy.2019;74(2):261-272.
122. Beretta C, Rifflart C, Evrard G, Jamart J, Thimpont J, Vandenplas O. Assessment of eosinophilic airway inflammation as a contribution to the diagnosis of occupational asthma. Allergy.2018;73(1):206-213.
123. Eguiluz-Gracia I, Tay TR, Hew M, et al. Recent developments and highlights in biomarkers in allergic diseases and asthma.Allergy. 2018;73(12):2290-2305.
124. Tan HT, Hagner S, Ruchti F, et al. Tight junction, mucin, and inflammasome-related molecules are differentially expressed in eosinophilic, mixed, and neutrophilic experimental asthma in mice.Allergy. 2019;74(2):294-307.
125. Boudier A, Chanoine S, Accordini S, et al. Data-driven adult asthma phenotypes based on clinical characteristics are associated with asthma outcomes twenty years later. Allergy. 2019;74(5):953-963.
126. Ivanova O, Richards LB, Vijverberg SJ, et al. What did we learn from multiple omics studies in asthma? Allergy.2019;74(11):2129-2145.
127. Su MW, Lin WC, Tsai CH, et al. Childhood asthma clusters reveal neutrophil-predominant phenotype with distinct gene expression.Allergy. 2018;73(10):2024-2032.
128. Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023-1042.
129. Agache I, Rocha C, Beltran J, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.Allergy. 2020;75(5):1043-1057.
130. Agache I, Song Y, Rocha C, et al. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma.Allergy. 2020;75(5):1058-1068.
131. Howarth P, Quirce S, Papi A, et al. Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma.Allergy. 2020.
132. Kuo CS, Pavlidis S, Zhu J, et al. Contribution of airway eosinophils in airway wall remodeling in asthma: Role of MMP-10 and MET.Allergy. 2019;74(6):1102-1112.
133. Sabogal Pineros YS, Bal SM, Dijkhuis A, et al. Eosinophils capture viruses, a capacity that is defective in asthma. Allergy.2019;74(10):1898-1909.
134. Tarancon R, Uranga S, Martin C, Aguilo N. Mycobacterium tuberculosis infection prevents asthma and abrogates eosinophilopoiesis in an experimental model. Allergy. 2019;74(12):2512-2514.
135. Bagnasco D, Massolo A, Bonavia M, et al. The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life. Allergy. 2020;75(6):1460-1463.
136. Jesenak M, Diamant Z. Blood eosinophils: In quest of a Holy Grail for personalized asthma treatment with biologicals. Allergy.2020;75(6):1294-1297.
137. Casale TB, Chipps BE, Rosen K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.Allergy. 2018;73(2):490-497.
138. Rodrigo-Munoz JM, Canas JA, Sastre B, et al. Asthma diagnosis using integrated analysis of eosinophil microRNAs. Allergy.2019;74(3):507-517.
139. Granger V, Taille C, Roach D, et al. Circulating neutrophil and eosinophil extracellular traps are markers of severe asthma.Allergy. 2020;75(3):699-702.
140. Beuraud C, Lombardi V, Luce S, et al. CCR10(+) ILC2s with ILC1-like properties exhibit a protective function in severe allergic asthma.Allergy. 2019;74(5):933-943.
141. Hoang JA, Mashouri P, Dai R, et al. Extract and component-specific sensitization patterns in Canadian moderate-to-severe preschool asthmatics. Allergy. 2019;74(12):2519-2521.
142. Nieto-Fontarigo JJ, Gonzalez-Barcala FJ, Andrade-Bulos LJ, et al. iTRAQ-based proteomic analysis reveals potential serum biomarkers of allergic and nonallergic asthma. Allergy. 2020.
143. Pavord ID, Holliday M, Reddel HK, et al. Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. The Lancet Respiratory Medicine.2020;8(7):671-680.
144. Alvaro-Lozano M, Akdis CA, Akdis M, et al. EAACI Allergen Immunotherapy User’s Guide. Pediatr Allergy Immunol. 2020;31 Suppl 25(Suppl 25):1-101.
145. Agache I, Lau S, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. Allergy.2019;74(5):855-873.
146. Farraia M, Cavaleiro Rufo J, Paciência I, et al. Human volatilome analysis using eNose to assess uncontrolled asthma in a clinical setting. Allergy. 2020;75(7):1630-1639.
147. Abdel-Aziz MI, de Vries R, Lammers A, et al. Cross-sectional biomarker comparisons in asthma monitoring using a longitudinal design: The eNose premise. Allergy. 2020;doi: 10.1111/all.14354. Online ahead of print.
148. Cavaleiro Rufo J, Paciencia I, Mendes FC, et al. Exhaled breath condensate volatilome allows sensitive diagnosis of persistent asthma.Allergy. 2019;74(3):527-534.
149. Bousquet J, Hellings PW, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. J Allergy Clin Immunol. 2019;143(3):864-879.
150. Bédard A, Antó JM, Fonseca JA, et al. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air(®) App. Allergy. 2020;75(7):1672-1688.
151. Bousquet J, Arnavielhe S, Bedbrook A, et al. The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study.Allergy. 2018;73(2):505-510.
152. Bousquet J, Agache I, Aliberti MR, et al. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project). Allergy. 2018;73(1):77-92.
153. Peters MC, Wenzel SE. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. Lancet.2020;395(10221):371-383.
154. Fahy JV. Type 2 inflammation in asthma–present in most, absent in many. Nat Rev Immunol. 2015;15(1):57-65.
155. Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605.
156. McDowell PJ, Heaney LG. Different endotypes and phenotypes drive the heterogeneity in severe asthma. Allergy. 2020;75(2):302-310.
157. Ho T, Al-Selahi E, Mukherjee M, et al. Sputum and serum immunoglobulins in adult asthmatics with recurrent respiratory tract infections. Allergy. 2020.
158. Fieten KB, Rijssenbeek-Nouwens LH, Hashimoto S, Bel EH, Weersink EJ. Less exacerbations and sustained asthma control 12 months after high altitude climate treatment for severe asthma. Allergy.2019;74(3):628-630.
159. Fieten KB, Zijlstra WT, van Os-Medendorp H, et al. Comparing high altitude treatment with current best care in Dutch children with moderate to severe atopic dermatitis (and asthma): study protocol for a pragmatic randomized controlled trial (DAVOS trial). Trials.2014;15:94.
160. Boonpiyathad T, Capova G, Duchna HW, et al. Impact of high-altitude therapy on type-2 immune responses in asthma patients. Allergy.2020;75(1):84-94.
161. Seys SF, Quirce S, Agache I, et al. Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018. Allergy.2019;74(11):2244-2248.
162. Eyerich S, Metz M, Bossios A, Eyerich K. New biological treatments for asthma and skin allergies. Allergy. 2020;75(3):546-560.
163. Voorham J, Xu X, Price DB, et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy. 2019;74(2):273-283.
164. Papadopoulos NG, Barnes P, Canonica GW, et al. The evolving algorithm of biological selection in severe asthma. Allergy.2020;75(7):1555-1563.
165. Israel E, Reddel HK. Severe and Difficult-to-Treat Asthma in Adults. The New England journal of medicine.2017;377(10):965-976.
166. Chapman KR, Albers FC, Chipps B, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716-1726.
167. Mukherjee M, Bakakos P, Loukides S. New paradigm in asthma management: Switching between biologics! Allergy.2020;75(4):743-745.
168. Deschildre A, Roussel J, Drumez E, et al. Omalizumab discontinuation in children with severe allergic asthma: An observational real-life study. Allergy. 2019;74(5):999-1003.
169. Mathur SK, Modena BD, Coumou H, Barker P, Kreindler JL, Zangrilli JG. Postbronchodilator lung function improvements with benralizumab for patients with severe asthma. Allergy. 2020;75(6):1507-1510.
170. Antonicelli L, Tontini C, Marchionni A, Lucchetti B, Garritani MS, Bilò MB. Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma.Allergy. 2020;75(2):433-436.
171. Agache I, Akdis C, Akdis M, et al. EAACI Biologicals Guidelines-Recommendations for severe asthma. Allergy. 2020.
172. Lombardi C, Passalacqua G, Bagnasco D. Severe asthma, biologicals, and auto-injection: Yes, no, may be! Allergy. 2020;75(2):444-445.
173. Sokolowska M, Rovati GE, Diamant Z, et al. Current perspective on eicosanoids in asthma and allergic diseases - EAACI Task Force consensus report, part I. Allergy. 2020.
174. Maun HR, Jackman JK, Choy DF, et al. An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma.Cell. 2020;180(2):406.
175. Kere M, Gruzieva O, Ullemar V, et al. Effects of inhaled corticosteroids on DNA methylation in peripheral blood cells in children with asthma. Allergy. 2020;75(3):688-691.
176. Schmitt J, Wüstenberg E, Küster D, Mücke V, Serup-Hansen N, Tesch F. The moderating role of allergy immunotherapy in asthma progression: Results of a population-based cohort study. Allergy.2020;75(3):596-602.
177. Boonpiyathad T, Pradubpongsa P, Mitthamsiri W, Satitsuksanoa P, Jacquet A, Sangasapaviliya A. Allergen-specific immunotherapy boosts allergen-specific IgD production in house dust mite-sensitized asthmatic patients. Allergy. 2020;75(6):1457-1460.
178. Devillier P, Molimard M, Ansolabehere X, et al. Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France. Allergy.2019;74(7):1317-1326.
179. Wahn U, Bachert C, Heinrich J, Richter H, Zielen S. Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. Allergy. 2019;74(3):594-604.
180. Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis.Allergy. 2018;73(1):165-177.
181. Mösges R, Bachert C, Panzner P, et al. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial. Allergy.2018;73(9):1842-1850.
182. Asaria M, Dhami S, van Ree R, et al. Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview. Allergy.2018;73(2):269-283.
183. Hesse L, van Ieperen N, Habraken C, et al. Subcutaneous immunotherapy with purified Der p1 and 2 suppresses type 2 immunity in a murine asthma model. Allergy. 2018;73(4):862-874.
184. Crossman-Barnes CJ, Peel A, Fong-Soe-Khioe R, Sach T, Wilson A, Barton G. Economic evidence for nonpharmacological asthma management interventions: A systematic review. Allergy.2018;73(6):1182-1195.
185. Bousquet J, Jutel M, Akdis CA, et al. ARIA-EAACI statement on Asthma and COVID-19 (June 2, 2020). Allergy. 2020.
186. Avdeev S, Moiseev S, Brovko M, et al. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. Allergy. 2020.
187. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy.2020;75(7):1730-1741.
188. Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A. Is asthma protective against COVID-19? Allergy. 2020.
189. Johnston SL. Asthma and COVID-19: Is asthma a risk factor for severe outcomes? Allergy. 2020;75(7):1543-1545.
190. Beaney T, Salman D, Samee T, Mak V. Assessment and management of adults with asthma during the covid-19 pandemic. BMJ.2020;369:m2092.
191. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of asthma and its genetic predisposition with the risk of severe COVID-19. J Allergy Clin Immunol.2020;146(2):327-329.e324.
192. Licari A, Votto M, Brambilla I, et al. Allergy and asthma in children and adolescents during the COVID outbreak: What we know and how we could prevent allergy and asthma flares. Allergy. 2020.
193. Sokolowska M, Lukasik Z, Agache I, et al. Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives - a report of the European Academy of Allergy and Clinical Immunology (EAACI).Allergy. 2020.
194. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.Allergy. 2020;75(7):1564-1581.
195. Riggioni C, Comberiati P, Giovannini M, et al. A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy.2020.
196. Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020.
197. Wang JY, Pawankar R, Tsai HJ, Wu SL, Kuo WS. COVID-19 and Asthma, the Good or the Bad? Allergy. 2020.
198. Leonardi A, Fauquert JL, Doan S, et al. Managing ocular allergy in the time of COVID-19. Allergy. 2020.
199. Vultaggio A, Agache I, Akdis CA, et al. Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement. Allergy. 2020.
200. Pfaar O, Klimek L, Jutel M, et al. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic - an EAACI/ARIA Position Paper. Allergy. 2020.
201. Klimek L, Jutel M, Akdis C, et al. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement.Allergy. 2020;75(7):1546-1554.
202. Bousquet J, Akdis C, Jutel M, et al. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. Allergy. 2020.
203. Klimek L, Hagemann J, Alali A, et al. Telemedicine allows quantitative measuring of olfactory dysfunction in COVID-19.Allergy. 2020.
204. Akbarshahi H, Menzel M, Ramu S, Mahmutovic Persson I, Bjermer L, Uller L. House dust mite impairs antiviral response in asthma exacerbation models through its effects on TLR3. Allergy.2018;73(5):1053-1063.
205. Lommatzsch M, Stoll P, Virchow JC. COVID-19 in a patient with severe asthma treated with Omalizumab. Allergy. 2020.
206. Bilò MB, Pravettoni V, Mauro M, Bonadonna P. Treating venom allergy during COVID-19 pandemic. Allergy. 2020.